Improve patient care with genomic testing to tailor adjuvant systemic treatment in early HR+, HER2- breast cancer
Hybrid Satellite Symposium with Prof. Valentina Guarneri (Italy), Prof. Christos Markopoulos (Greece) and Prof. Richard Simcock (UK) at the St. Gallen International Breast Cancer Conference on the 15 March 2023 in Vienna, Austria.
EBCC 2022: Personalize adjuvant systemic treatment with genomic testing in early-stage HR+, HER2- breast cancer
Satellite Symposium with Prof. David Cameron (UK), Prof. Miguel Martín (Spain) and Prof. Joseph Gligorov (France). Thursday, 17 November 2022 at the European Breast Cancer Conference.
Advancing precision oncology with genomic testing in early-stage HR+, HER2- breast cancer
What evidence do we have to guide treatment decisions with genomic testing in early-stage HR+, HER2- breast cancer? Genomic testing in early-stage HR+, HER2- breast cancer – when and whom?
Guiding N1 treatment decisions after RxPONDER
Prof. Catherine Kelly from the Trinity St James Cancer Institute in Dublin presents the RxPONDER results.
Resultados iniciales de RxPONDER en la práctica clínica
El doctor Joan Albanell (España) y el doctor Mark Verrill (Reino Unido) evalúan los resultados iniciales de RxPONDER presentados en SABCS 2020 y el impacto que tienen en la práctica clínica.
Resultados iniciales de RxPONDER en la práctica clínica
El profesor Stephen Chia (Canadá) y el doctor Mark Verrill (Reino Unido) evalúan los resultados iniciales de RxPONDER presentados en SABCS 2020 y el impacto que tienen en la práctica clínica.
Clinical practice revisited: Improving chemotherapy treatment decisions in early-stage breast cancer
Prof. Hartkopf from the University of Tuebingen talks about the evidence from his clinical practice and which parameters guide treatment decisions in early-stage breast cancer. Prof. Thill form Agaplesion Markus Hospital discusses real-world evidence from the REMAR study and how treatment decisions are optimized with multigene testing.
Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment decisions in HER2-, HR+, early-stage breast cancer patients.
The Oncotype DX Breast Recurrence Score® assay in clinical practice
Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast Recurrence Score® assay evidence and in particular, the TAILORx landmark trial data.
Comuníquese con nosotros
¿Tiene preguntas sobre la prueba Oncotype DX®?
